muiltiple sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: lipoic acid supplement (1200mg/day) for 90 days. Intervention 2: control group: 2 capsuls including dietary fiber.
Treatment - Drugs
Placebo
lipoic acid supplement (1200mg/day) for 90 days
control group: 2 capsuls including dietary fiber
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 51 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age 18-51 years, able to provide informed consent and diagnosed with relapsing remitting MS. Exclusion criteria: MS exacerbation during the study, systemically administered corticosteroids during the study , pregnant or breast-feeding , other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus and other autoimmune disease) that might increase the risk of subject experiencing adverse events. Consumption of vitamin, mineral and antioxidant supplement 30 days before study entry, Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study and compliance less than 70%.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease serum lipoic acid concentration. Timepoint: 12 week. Method of measurement: HPLC.;Decrease serum TNF-a concentration. Timepoint: 12 week. Method of measurement: labratory kit.;Decrease serum MDA concentration. Timepoint: 12 week. Method of measurement: Spectrophotometry.;Increase SOD. Timepoint: 12 week. Method of measurement: Spectrophotometry.;Increase glutathione peroxidase. Timepoint: 12 week. Method of measurement: Spectrophotometry.;Decrease serum ADA concentration. Timepoint: 12 week. Method of measurement: ELYSA.;Decrease serum INF-y concentration. Timepoint: 12 week. Method of measurement: ELYSA.;Increase TGF-B. Timepoint: 12 week. Method of measurement: ELYSA.;Increase IL-6. Timepoint: 12 week. Method of measurement: ELYSA.;Increase IL-4. Timepoint: 12 week. Method of measurement: ELYSA.;Decrease MMP-9. Timepoint: 12 week. Method of measurement: ELYSA.;Decrease VCAM-1. Timepoint: 12 week. Method of measurement: ELYSA.;Decrease ICAM-1. Timepoint: 12 week. Method of measurement: ELYSA.;TAC. Timepoint: 12 week. Method of measurement: colorimetry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease EDSS. Timepoint: 12 week. Method of measurement: observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahriar Eghtesadi
School of Health, Iran University of Medical Sciences
Outcome results
None listed